{
 "awd_id": "2132838",
 "agcy_id": "NSF",
 "tran_type": "CoopAgrmnt",
 "awd_istr_txt": "Cooperative Agreement",
 "awd_titl_txt": "SBIR Phase II:  Non-Chromatographic Method for the Purification of Viral Vectors",
 "cfda_num": "47.041, 47.084",
 "org_code": "15030000",
 "po_phone": "7032924392",
 "po_email": "amonk@nsf.gov",
 "po_sign_block_name": "Alastair Monk",
 "awd_eff_date": "2022-03-01",
 "awd_exp_date": "2024-02-29",
 "tot_intn_awd_amt": 902504.0,
 "awd_amount": 902504.0,
 "awd_min_amd_letter_date": "2022-02-17",
 "awd_max_amd_letter_date": "2022-02-17",
 "awd_abstract_narration": "The broader impact /commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the creation of a scalable platform technology to deliver new therapies and vaccines through manufacturing viral vectors. This sector has been hampered by inefficient manufacturing methods designed for small molecules 10,000 times less complex than the current effort. The technology developed herein will provide a durable competitive advantage by offering \u201cplug and play,\u201d broad compatibility, and improved productivity for virus manufacturing compared to existing industry solutions. The technology will improve yields, shorten manufacturing lead times, and accelerate time-to-market for potentially life-saving therapies and vaccines. This research project seeks to validate scalability and establish a production method to deliver quality reagents to developers of adenoviral vectors.  \r\n\r\nThis Small Business Innovation Research (SBIR) Phase II project seeks to advance a scalable downstream purification process for gene therapy vectors.  Viral vectors have remarkable utility as therapeutics and vaccines, but their impact has been plagued by downstream purification inefficiencies that lead to single digit yields.  The technology developed in this project will address this bottleneck using a polypeptide-based reagent that combines affinity-capture with phase separation and filtration equipment. The technology aims to improve capacity, step yield, final vector purity, and productivity. To validate the lead adenovirus reagent, a tangential flow filtration process will be optimized using harvests with a wide range of starting impurities and across various adenovirus serotypes to ensure a broadly compatible product. The reagent\u2019s ability to stabilize adenovirus will be further explored toward an efficient and scalable filtration process. Finally, a method for reagent manufacturing will be developed to ensure consistent and low-cost supply. Completion of these objectives will yield a mature downstream process for one-step adenovirus purification, a manufacturing method that ensures sufficient quantity of quality reagents to support adenovirus clinical development, and rapidly deployable adenovirus vaccine manufacturing to meet future needs.\r\n\r\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.",
 "awd_arra_amount": 0.0,
 "dir_abbr": "TIP",
 "org_dir_long_name": "Directorate for Technology, Innovation, and Partnerships",
 "div_abbr": "TI",
 "org_div_long_name": "Translational Impacts",
 "awd_agcy_code": "4900",
 "fund_agcy_code": "4900",
 "pi": [
  {
   "pi_role": "Principal Investigator",
   "pi_first_name": "Kelli",
   "pi_last_name": "Luginbuhl",
   "pi_mid_init": "M",
   "pi_sufx_name": "",
   "pi_full_name": "Kelli M Luginbuhl",
   "pi_email_addr": "kluginbuhl@isolerebio.com",
   "nsf_id": "000761520",
   "pi_start_date": "2022-02-17",
   "pi_end_date": null
  }
 ],
 "inst": {
  "inst_name": "Isolere Bio, Inc",
  "inst_street_address": "701 W MAIN ST",
  "inst_street_address_2": "STE 410",
  "inst_city_name": "DURHAM",
  "inst_state_code": "NC",
  "inst_state_name": "North Carolina",
  "inst_phone_num": "7193224394",
  "inst_zip_code": "277015013",
  "inst_country_name": "United States",
  "cong_dist_code": "04",
  "st_cong_dist_code": "NC04",
  "org_lgl_bus_name": "ISOLERE BIO INC",
  "org_prnt_uei_num": "UES5F4AAZJK5",
  "org_uei_num": "U9LXLSXNME74"
 },
 "perf_inst": {
  "perf_inst_name": "Isolere Bio, Inc",
  "perf_str_addr": "701 West Main Street, Suite 410",
  "perf_city_name": "Durham",
  "perf_st_code": "NC",
  "perf_st_name": "North Carolina",
  "perf_zip_code": "277015013",
  "perf_ctry_code": "US",
  "perf_cong_dist": "04",
  "perf_st_cong_dist": "NC04",
  "perf_ctry_name": "United States",
  "perf_ctry_flag": "1"
 },
 "pgm_ele": [
  {
   "pgm_ele_code": "537300",
   "pgm_ele_name": "SBIR Phase II"
  }
 ],
 "pgm_ref": [
  {
   "pgm_ref_code": "1982",
   "pgm_ref_txt": "BIOLOGICAL CHEMISTRY"
  }
 ],
 "app_fund": [
  {
   "app_code": "",
   "app_name": "",
   "app_symb_id": "",
   "fund_code": "01002223DB",
   "fund_name": "NSF RESEARCH & RELATED ACTIVIT",
   "fund_symb_id": "040100"
  }
 ],
 "oblg_fy": [
  {
   "fund_oblg_fiscal_yr": 2022,
   "fund_oblg_amt": 902504.0
  }
 ],
 "por": {
  "por_cntn": "<div class=\"porColContainerWBG\">\n<div class=\"porContentCol\"><div class=\"OutlineElement Ltr SCXW131559280 BCX8\">\n<p class=\"Paragraph SCXW131559280 BCX8\"><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW131559280 BCX8\">Th</span><span class=\"NormalTextRun SCXW131559280 BCX8\">is </span><span class=\"NormalTextRun SCXW131559280 BCX8\">NSF SBIR Phase II project, titled &ldquo;</span></span><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\">SBIR Phase II: Non-Chromatographic Method for the Purification of Viral Vectors&rdquo;</span><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW131559280 BCX8\">&nbsp;encompasses two major goals: </span><span class=\"NormalTextRun SCXW131559280 BCX8\">(1)</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> t</span><span class=\"NormalTextRun SCXW131559280 BCX8\">o develop</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> a scalable tangential flow filtration (TFF) process for lentiviral vector (LV) manufacturing and </span><span class=\"NormalTextRun SCXW131559280 BCX8\">(2) to </span><span class=\"NormalTextRun SCXW131559280 BCX8\">conduct </span><span class=\"NormalTextRun SCXW131559280 BCX8\">optimization and </span><span class=\"NormalTextRun SCXW131559280 BCX8\">pilot </span><span class=\"NormalTextRun SCXW131559280 BCX8\">manufacturing</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> for </span><span class=\"NormalTextRun SCXW131559280 BCX8\">the</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> IsoTag&trade; LV reagent.&nbsp;</span><span class=\"NormalTextRun SCXW131559280 BCX8\">These goals aim to prepare this innovative product for the next commercial development stage.</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&nbsp;</span></span></p>\n</div>\n<div class=\"OutlineElement Ltr SCXW131559280 BCX8\">\n<p class=\"Paragraph SCXW131559280 BCX8\"><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW131559280 BCX8\">During this project, </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">Isolere</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> engaged in activities to </span><span class=\"NormalTextRun SCXW131559280 BCX8\">develop and </span><span class=\"NormalTextRun SCXW131559280 BCX8\">optimize</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> the </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV </span><span class=\"NormalTextRun SCXW131559280 BCX8\">reagent and </span><span class=\"NormalTextRun SCXW131559280 BCX8\">accompanying</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">tangential flow filtration (</span><span class=\"NormalTextRun SCXW131559280 BCX8\">TFF</span><span class=\"NormalTextRun SCXW131559280 BCX8\">)</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> process at a </span><span class=\"NormalTextRun AdvancedProofingIssueV2Themed SCXW131559280 BCX8\">200 m</span><span class=\"NormalTextRun SCXW131559280 BCX8\">L scale, addressing the need for </span><span class=\"NormalTextRun SCXW131559280 BCX8\">improved recovery</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">and a</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> commercial</span><span class=\"NormalTextRun SCXW131559280 BCX8\">ly scalable</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> process.</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> The parameters optimized during this project include the</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&nbsp;hollow fiber pore sizes,</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&nbsp;</span><span class=\"NormalTextRun SCXW131559280 BCX8\">buffer recipes</span><span class=\"NormalTextRun SCXW131559280 BCX8\">,</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&nbsp;</span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV </span><span class=\"NormalTextRun SCXW131559280 BCX8\">reagent </span><span class=\"NormalTextRun SCXW131559280 BCX8\">concentration, load, and shear among others</span><span class=\"NormalTextRun SCXW131559280 BCX8\">.</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">The resulting TFF process</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&nbsp;</span><span class=\"NormalTextRun SCXW131559280 BCX8\">is </span><span class=\"NormalTextRun SCXW131559280 BCX8\">a two-step approach: first concentrati</span><span class=\"NormalTextRun SCXW131559280 BCX8\">ng and purifying</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> the LV harvest with </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV </span><span class=\"NormalTextRun SCXW131559280 BCX8\">reagent </span><span class=\"NormalTextRun SCXW131559280 BCX8\">droplets and then removing the </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV using a small pore hollow fiber and a </span><span class=\"NormalTextRun SCXW131559280 BCX8\">buffer</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&nbsp;</span><span class=\"NormalTextRun SCXW131559280 BCX8\">selected to </span><span class=\"NormalTextRun SCXW131559280 BCX8\">resolubilize and </span><span class=\"NormalTextRun SCXW131559280 BCX8\">elute the </span><span class=\"NormalTextRun SCXW131559280 BCX8\">reagent while </span><span class=\"NormalTextRun SCXW131559280 BCX8\">retaining</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> highly pure, concentrated LV</span><span class=\"NormalTextRun SCXW131559280 BCX8\">.</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> This rigorous optimization exercise led to a process with over 90% step yield in both capture and elution steps.</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">Regarding</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> LV purity, </span><span class=\"NormalTextRun SCXW131559280 BCX8\">this process </span><span class=\"NormalTextRun SCXW131559280 BCX8\">achieved</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&nbsp;four-</span><span class=\"NormalTextRun SCXW131559280 BCX8\">log reduction in host cell proteins and removed </span><span class=\"NormalTextRun SCXW131559280 BCX8\">host cell DNA to undetectable levels.</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV removal is an area of active development</span><span class=\"NormalTextRun SCXW131559280 BCX8\">, </span><span class=\"NormalTextRun SCXW131559280 BCX8\">with the current protocol</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> a</span><span class=\"NormalTextRun SCXW131559280 BCX8\">chieving</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">2-log reduction</span><span class=\"NormalTextRun SCXW131559280 BCX8\">.</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span></span><span class=\"EOP CommentStart SCXW131559280 BCX8\">&nbsp;</span></p>\n</div>\n<div class=\"OutlineElement Ltr SCXW131559280 BCX8\">\n<p class=\"Paragraph SCXW131559280 BCX8\"><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW131559280 BCX8\">Externally, the process was tested at more than three sites using 100-</span><span class=\"NormalTextRun AdvancedProofingIssueV2Themed SCXW131559280 BCX8\">200 m</span><span class=\"NormalTextRun SCXW131559280 BCX8\">L of LV harvest material, achieving membrane loading of 100 L/m2 with optimized conditions. Internal scale-up </span><span class=\"NormalTextRun SCXW131559280 BCX8\">demonstrations </span><span class=\"NormalTextRun SCXW131559280 BCX8\">reached 1L, resulting in functional LV recoveries of 70%. However, due to the cost of LV, further internal scaling was </span><span class=\"NormalTextRun SCXW131559280 BCX8\">deemed</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> impracticable. Instead, </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">Isolere</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> is in discussions with </span><span class=\"NormalTextRun SCXW131559280 BCX8\">several collaborators detailing project scope</span><span class=\"NormalTextRun SCXW131559280 BCX8\">s</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> to scale the purification process to 2-5 and then 10</span><span class=\"NormalTextRun SCXW131559280 BCX8\">-50</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> L.</span></span><span class=\"EOP SCXW131559280 BCX8\">&nbsp;</span></p>\n</div>\n<div class=\"OutlineElement Ltr SCXW131559280 BCX8\">\n<p class=\"Paragraph SCXW131559280 BCX8\"><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW131559280 BCX8\">The project achieved several key outcomes, including testing of the </span><span class=\"NormalTextRun AdvancedProofingIssueV2Themed SCXW131559280 BCX8\">200 m</span><span class=\"NormalTextRun SCXW131559280 BCX8\">L TFF purification process at </span><span class=\"NormalTextRun SCXW131559280 BCX8\">more than</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> three external sites and the creation of an LV purification process recovering more than 70% of functional LV particles in under 6 hours</span><span class=\"NormalTextRun SCXW131559280 BCX8\">. </span><span class=\"NormalTextRun SCXW131559280 BCX8\">This work</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> was shared though </span><span class=\"NormalTextRun SCXW131559280 BCX8\">presentations at four conferences</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> and in a peer-reviewed</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> publication.</span></span><span class=\"EOP SCXW131559280 BCX8\">&nbsp;</span></p>\n</div>\n<div class=\"OutlineElement Ltr SCXW131559280 BCX8\">\n<p class=\"Paragraph SCXW131559280 BCX8\"><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW131559280 BCX8\">Towards the second </span><span class=\"NormalTextRun SCXW131559280 BCX8\">goal of </span><span class=\"NormalTextRun SCXW131559280 BCX8\">pilot</span><span class=\"NormalTextRun SCXW131559280 BCX8\">ing</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> manufacturing</span><span class=\"NormalTextRun SCXW131559280 BCX8\">, </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">Isolere</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">completed</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> upstream and downstream development </span><span class=\"NormalTextRun SCXW131559280 BCX8\">to produce</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">reagent</span><span class=\"NormalTextRun SCXW131559280 BCX8\">, followed by</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> three</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> pilot </span><span class=\"NormalTextRun SCXW131559280 BCX8\">manufacturing runs</span><span class=\"NormalTextRun SCXW131559280 BCX8\">.&nbsp; Production methods</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&nbsp;were significantly optimized resulting in &gt;</span><span class=\"NormalTextRun CommentStart CommentHighlightPipeRest CommentHighlightRest SCXW131559280 BCX8\">10x</span><span class=\"NormalTextRun CommentHighlightPipeRest SCXW131559280 BCX8\"> improvement in productivity from </span><span class=\"NormalTextRun SCXW131559280 BCX8\">initial</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> tech transfer of the research-scale manufacturing method.</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> The team </span><span class=\"NormalTextRun SCXW131559280 BCX8\">demonstrated</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> consistent production </span><span class=\"NormalTextRun SCXW131559280 BCX8\">and purification</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">with acceptable levels of productivity that aligned with cost-effective </span><span class=\"NormalTextRun SCXW131559280 BCX8\">commercial</span><span class=\"NormalTextRun SCXW131559280 BCX8\">ization of the product</span><span class=\"NormalTextRun SCXW131559280 BCX8\">.&nbsp;</span></span><span class=\"EOP SCXW131559280 BCX8\">&nbsp;</span></p>\n</div>\n<div class=\"OutlineElement Ltr SCXW131559280 BCX8\">\n<p class=\"Paragraph SCXW131559280 BCX8\"><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW131559280 BCX8\">Residual assay development, </span><span class=\"NormalTextRun SCXW131559280 BCX8\">initiated</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> with a third party, </span><span class=\"NormalTextRun SCXW131559280 BCX8\">has resulted in</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> beta kits capable of detecting </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV with nanomolar sensitivity. Additionally, an activity assay was developed internally to measure the binding efficiency of </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> to nanomolar specificity</span><span class=\"NormalTextRun SCXW131559280 BCX8\">, crucial for </span><span class=\"NormalTextRun SCXW131559280 BCX8\">determining</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">functional testing and </span><span class=\"NormalTextRun SCXW131559280 BCX8\">acceptance criteria for </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV </span><span class=\"NormalTextRun SCXW131559280 BCX8\">reagent </span><span class=\"NormalTextRun SCXW131559280 BCX8\">batch release</span><span class=\"NormalTextRun SCXW131559280 BCX8\">.</span></span><span class=\"EOP SCXW131559280 BCX8\">&nbsp;</span></p>\n</div>\n<div class=\"OutlineElement Ltr SCXW131559280 BCX8\">\n<p class=\"Paragraph SCXW131559280 BCX8\"><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW131559280 BCX8\">With these activities complete, we are now producing material to support prototype launch of the </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV reagent with higher-grade product launches </span><span class=\"NormalTextRun SCXW131559280 BCX8\">coming soon</span><span class=\"NormalTextRun SCXW131559280 BCX8\">.&nbsp;</span></span><span class=\"EOP SCXW131559280 BCX8\">&nbsp;</span></p>\n</div>\n<div class=\"OutlineElement Ltr SCXW131559280 BCX8\">\n<p class=\"Paragraph SCXW131559280 BCX8\"><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW131559280 BCX8\">Th</span><span class=\"NormalTextRun SCXW131559280 BCX8\">is NSF-funded SBIR</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> project addresses the growing challenges in cell therapy manufacturing, where the number of worldwide trials is expected to reach 8,000 by 2026. </span><span class=\"NormalTextRun SCXW131559280 BCX8\">One of the major </span><span class=\"NormalTextRun SCXW131559280 BCX8\">bottleneck</span><span class=\"NormalTextRun SCXW131559280 BCX8\">s today</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> lies in the </span><span class=\"NormalTextRun SCXW131559280 BCX8\">production of LV due to </span><span class=\"NormalTextRun SCXW131559280 BCX8\">inefficient downstream processes, resulting in low yields (10-25%) and a significant volumetric burden</span><span class=\"NormalTextRun SCXW131559280 BCX8\">. The </span><span class=\"NormalTextRun SCXW131559280 BCX8\">bio</span><span class=\"NormalTextRun SCXW131559280 BCX8\">manufacturing</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> industry relies on chromatography steps, such as anion exchange chromatography (AEX) and size-exclusion chromatography (SEC), but these methods are cumbersome and have low recoveries</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> for large targets like LV</span><span class=\"NormalTextRun SCXW131559280 BCX8\">.</span></span><span class=\"EOP SCXW131559280 BCX8\">&nbsp;</span></p>\n</div>\n<div class=\"OutlineElement Ltr SCXW131559280 BCX8\">\n<p class=\"Paragraph SCXW131559280 BCX8\"><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">Isolere's</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> innovative approach involves a recombinant protein</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">reagent engineered </span><span class=\"NormalTextRun SCXW131559280 BCX8\">to combine the powers of both</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">affinity</span><span class=\"NormalTextRun SCXW131559280 BCX8\">-</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> and </span><span class=\"NormalTextRun SCXW131559280 BCX8\">size- based separation</span><span class=\"NormalTextRun SCXW131559280 BCX8\">.</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> This technology streamlines the purification of</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">LV</span><span class=\"NormalTextRun SCXW131559280 BCX8\">, a critical </span><span class=\"NormalTextRun SCXW131559280 BCX8\">component</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> in cell and gene therapies. Unlike current methods, </span><span class=\"NormalTextRun SCXW131559280 BCX8\">the</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">process </span><span class=\"NormalTextRun SCXW131559280 BCX8\">using</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV reagent</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">does not require </span><span class=\"NormalTextRun SCXW131559280 BCX8\">chromatography</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> and</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">offers streamlining of purification into ju</span><span class=\"NormalTextRun SCXW131559280 BCX8\">s</span><span class=\"NormalTextRun SCXW131559280 BCX8\">t two filtration</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> steps. </span><span class=\"NormalTextRun SCXW131559280 BCX8\">We expect the reagent and process developed </span><span class=\"NormalTextRun SCXW131559280 BCX8\">herein</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> to make</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> a significant impact on the biomanufacturing industry by offering commercially scalable methods with superior yields and </span><span class=\"NormalTextRun SCXW131559280 BCX8\">purity, as well as</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">greater functional </span><span class=\"NormalTextRun SCXW131559280 BCX8\">LV recover</span><span class=\"NormalTextRun SCXW131559280 BCX8\">y</span><span class=\"NormalTextRun SCXW131559280 BCX8\">.</span></span><span class=\"EOP SCXW131559280 BCX8\">&nbsp;</span></p>\n</div>\n<div class=\"OutlineElement Ltr SCXW131559280 BCX8\">\n<p class=\"Paragraph SCXW131559280 BCX8\"><span class=\"TextRun SCXW131559280 BCX8\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXW131559280 BCX8\">By enhancing the efficiency of LV purification with the </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">IsoTag</span><span class=\"NormalTextRun SCXW131559280 BCX8\">&trade; LV </span><span class=\"NormalTextRun SCXW131559280 BCX8\">reagent and</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> reducing</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> the number of</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> downstream steps</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">required</span><span class=\"NormalTextRun SCXW131559280 BCX8\">, there are clear benefits beyond LV recovery improvement</span><span class=\"NormalTextRun SCXW131559280 BCX8\">. This </span><span class=\"NormalTextRun SCXW131559280 BCX8\">process </span><span class=\"NormalTextRun SCXW131559280 BCX8\">not only diminishes the upstream burden but also minimizes the manufacturing footprint and resource requirements, making the process more sustainable.</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">Importantly, the societal impact of this project extends to accessibility and affordability of </span><span class=\"NormalTextRun SCXW131559280 BCX8\">the many</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> therapeutics</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> requiring LV vectors, i</span><span class=\"NormalTextRun SCXW131559280 BCX8\">ncluding</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> </span><span class=\"NormalTextRun SCXW131559280 BCX8\">numerous</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> CAR-T cell therapies and virus-like vacci</span><span class=\"NormalTextRun SCXW131559280 BCX8\">nes</span><span class=\"NormalTextRun SCXW131559280 BCX8\">.</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> The </span><span class=\"NormalTextRun SCXW131559280 BCX8\">high cost</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> of current LV therapies, ranging from $0.4-3 million per dose, poses a barrier to access f</span><span class=\"NormalTextRun SCXW131559280 BCX8\">or many. </span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW131559280 BCX8\">Isolere's</span><span class=\"NormalTextRun SCXW131559280 BCX8\"> technology has the potential to lower production costs, making life-saving therapies more accessible to a broader population.&nbsp;</span></span><span class=\"EOP SCXW131559280 BCX8\">&nbsp;</span></p>\n</div><br>\n<p>\n Last Modified: 02/02/2024<br>\nModified by: Kelli&nbsp;M&nbsp;Luginbuhl</p></div>\n<div class=\"porSideCol\"\n></div>\n</div>\n",
  "por_txt_cntn": "\n\n\nThis NSF SBIR Phase II project, titled SBIR Phase II: Non-Chromatographic Method for the Purification of Viral Vectorsencompasses two major goals: (1) to develop a scalable tangential flow filtration (TFF) process for lentiviral vector (LV) manufacturing and (2) to conduct optimization and pilot manufacturing for the IsoTag LV reagent.These goals aim to prepare this innovative product for the next commercial development stage.\n\n\n\n\nDuring this project, Isolere engaged in activities to develop and optimize the IsoTag LV reagent and accompanying tangential flow filtration (TFF) process at a 200 mL scale, addressing the need for improved recovery and a commercially scalable process. The parameters optimized during this project include thehollow fiber pore sizes,buffer recipes,IsoTag LV reagent concentration, load, and shear among others. The resulting TFF processis a two-step approach: first concentrating and purifying the LV harvest with IsoTag LV reagent droplets and then removing the IsoTag LV using a small pore hollow fiber and a bufferselected to resolubilize and elute the reagent while retaining highly pure, concentrated LV. This rigorous optimization exercise led to a process with over 90% step yield in both capture and elution steps. Regarding LV purity, this process achievedfour-log reduction in host cell proteins and removed host cell DNA to undetectable levels. IsoTag LV removal is an area of active development, with the current protocol achieving 2-log reduction. \n\n\n\n\nExternally, the process was tested at more than three sites using 100-200 mL of LV harvest material, achieving membrane loading of 100 L/m2 with optimized conditions. Internal scale-up demonstrations reached 1L, resulting in functional LV recoveries of 70%. However, due to the cost of LV, further internal scaling was deemed impracticable. Instead, Isolere is in discussions with several collaborators detailing project scopes to scale the purification process to 2-5 and then 10-50 L.\n\n\n\n\nThe project achieved several key outcomes, including testing of the 200 mL TFF purification process at more than three external sites and the creation of an LV purification process recovering more than 70% of functional LV particles in under 6 hours. This work was shared though presentations at four conferences and in a peer-reviewed publication.\n\n\n\n\nTowards the second goal of piloting manufacturing, Isolere completed upstream and downstream development to produce IsoTag LV reagent, followed by three pilot manufacturing runs. Production methodswere significantly optimized resulting in 10x improvement in productivity from initial tech transfer of the research-scale manufacturing method. The team demonstrated consistent production and purification with acceptable levels of productivity that aligned with cost-effective commercialization of the product.\n\n\n\n\nResidual assay development, initiated with a third party, has resulted in beta kits capable of detecting IsoTag LV with nanomolar sensitivity. Additionally, an activity assay was developed internally to measure the binding efficiency of IsoTag LV to nanomolar specificity, crucial for determining functional testing and acceptance criteria for IsoTag LV reagent batch release.\n\n\n\n\nWith these activities complete, we are now producing material to support prototype launch of the IsoTag LV reagent with higher-grade product launches coming soon.\n\n\n\n\nThis NSF-funded SBIR project addresses the growing challenges in cell therapy manufacturing, where the number of worldwide trials is expected to reach 8,000 by 2026. One of the major bottlenecks today lies in the production of LV due to inefficient downstream processes, resulting in low yields (10-25%) and a significant volumetric burden. The biomanufacturing industry relies on chromatography steps, such as anion exchange chromatography (AEX) and size-exclusion chromatography (SEC), but these methods are cumbersome and have low recoveries for large targets like LV.\n\n\n\n\nIsolere's innovative approach involves a recombinant protein reagent engineered to combine the powers of both affinity- and size- based separation. This technology streamlines the purification of LV, a critical component in cell and gene therapies. Unlike current methods, the process using IsoTag LV reagent does not require chromatography and offers streamlining of purification into just two filtration steps. We expect the reagent and process developed herein to make a significant impact on the biomanufacturing industry by offering commercially scalable methods with superior yields and purity, as well as greater functional LV recovery.\n\n\n\n\nBy enhancing the efficiency of LV purification with the IsoTag LV reagent and reducing the number of downstream steps required, there are clear benefits beyond LV recovery improvement. This process not only diminishes the upstream burden but also minimizes the manufacturing footprint and resource requirements, making the process more sustainable. Importantly, the societal impact of this project extends to accessibility and affordability of the many therapeutics requiring LV vectors, including numerous CAR-T cell therapies and virus-like vaccines. The high cost of current LV therapies, ranging from $0.4-3 million per dose, poses a barrier to access for many. Isolere's technology has the potential to lower production costs, making life-saving therapies more accessible to a broader population.\n\t\t\t\t\tLast Modified: 02/02/2024\n\n\t\t\t\t\tSubmitted by: KelliMLuginbuhl\n"
 }
}